InMed’s INM-901 Cuts IL-6, IL-8 in 3D Brain Organoids, De-Risks Alzheimer’s Program
InMed’s INM-901 cut IL-6 and IL-8 levels in two 3D human brain organoid Alzheimer’s models, matching prior in vivo reductions of IFN-γ and TNF-α and de-risking its neuroinflammation program. The company plans a pre-IND meeting in Q3 2026 and targets an IND filing and Phase 1 trial in 2027.
1. Positive 3D Brain Organoid Results
InMed’s INM-901 demonstrated a dose-dependent reduction of IL-6 and IL-8 in two human brain organoid models—including a general LPS/IFN-γ-induced neuroinflammation system and a proprietary Alzheimer’s disease-specific model—validating anti-inflammatory activity in complex human 3D neural tissue.
2. Alignment with Preclinical Findings
These organoid results mirror prior in vivo Alzheimer’s disease mouse data showing lowered IFN-γ, TNF-α, IL-1β and neurofilament light chain, as well as ex vivo LPS-induced neuroinflammation studies that reported NLRP3 inflammasome inhibition, reinforcing translational confidence.
3. Regulatory and Development Roadmap
InMed plans a pre-IND meeting with the FDA in Q3 2026 and aims to complete IND-enabling pharmacology, toxicology and manufacturing scale-up for INM-901, targeting an IND submission and Phase 1 trial initiation in 2027.